CN105268320A - Ultrafiltration technology of injection for MRI or CT radiography - Google Patents
Ultrafiltration technology of injection for MRI or CT radiography Download PDFInfo
- Publication number
- CN105268320A CN105268320A CN201410260510.2A CN201410260510A CN105268320A CN 105268320 A CN105268320 A CN 105268320A CN 201410260510 A CN201410260510 A CN 201410260510A CN 105268320 A CN105268320 A CN 105268320A
- Authority
- CN
- China
- Prior art keywords
- milipore filter
- filter bag
- ultrafiltration
- parenteral solution
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses an ultrafiltration technology of an injection for MRI or CT radiography. According to the ultrafiltration technology, ultrafiltration adopts polyether sulfone 10kD ultrafiltration membrane packages, and area of a single membrane package is 1-2 m<2>; and two ultrafiltration membrane packages are used in the ultrafiltration technology and are respectively a first ultrafiltration membrane package and a second ultrafiltration membrane package which are connected in series, and a sampling point is set between the two ultrafiltration membrane packages; after detection of a filtrate which has passed through the first ultrafiltration membrane package, the filtrate is filtrated by the second ultrafiltration membrane package if bacterial endotoxin level of the filtrate is no less than 0.2 EU/ml, so as to obtain a final filtrate. The inventor creatively adopts the two specific series-connected ultrafiltration membrane packages and explores the optimum technological parameters and category of the ultrafiltration membrane packages. Thus, industrial application of the ultrafiltration technology of a high-viscosity injection is realized. The pH decreasing caused by using active carbon to remove bacterial endotoxin is avoided, and the technology is simpler. Low level of bacterial endotoxin in the product is guaranteed, and production cost is further reduced.
Description
Technical field
The present invention relates to a kind of ultrafiltration technology of medicinal liquid injection, specifically, relate to a kind of full-bodied MRI or CT radiography parenteral solution improve after, for removing the ultrafiltration technology of bacterial endotoxin.
Background technology
MRI or CT radiography parenteral solution is as a kind of parenteral solution of intravenously administrable, and the bacteria endotoxin content in product is key control point.In parenteral solution production process in the past, have employed active carbon adsorption and remove bacterial endotoxin in solution.
Active carbon is except adsorbing except certain bacterial endotoxin, can also play to the effect of solution decolouring, but it is larger on the pH value impact of MRI or CT radiography parenteral solution, linearly reduce, 0.5% activated carbon dosage, reduce 0.5pH unit, so only have employed the activated carbon dosage of 0.1% in our production technology, this limits its suction-operated to bacterial endotoxin to a certain extent.All the time, do not find the method more suitably removing bacterial endotoxin, the introducing of strict control of heat source can only be set about from production water for injection, raw material, interior packaging material aspect, also improve production cost simultaneously.
In recent years, hyperfiltration technique, in purification of water quality, achieves successfully.In order to improve the production technology of MRI or CT radiography parenteral solution, save production cost, we have also carried out the relevant exploration of this respect.
But, as everyone knows, MRI or CT radiography parenteral solution has an outstanding feature, and the content being exactly main ingredient is very high, such as iohexol inj is domestic at present 300mgI/ml and 350mgI/ml equal-specification, and Iohexol content is wherein considerably beyond 50% (w/w).According to the research of doctor Luo Shineng in " research of non-ionic x-ray contrast medium Iohexol and iohexol inj ", the viscosity of iohexol inj and the biquadratic of product design are proportionate, and therefore the product viscosity of the iohexol inj of high concentration is very large.Iodine class contrast preparation and gadolinium class contrast preparation product viscosity are greatly its common features.And this products characteristics determines the difficulty of common hyperfiltration technique industrial applications.
Summary of the invention
In order to solve above-mentioned technical barrier of the prior art, the invention provides a kind of ultrafiltration technology of MRI or CT radiography parenteral solution, this technique can not only decrease the dependence of the milipore filter bag to specific high standard, improve the rate of recovery of main ingredient, and the bacterial endotoxin caused because of problems such as flow velocity, pressure, film integralities in one-level ultra-filtration process can be avoided retain not exclusively, cause the underproof problem of product quality.
The object of the invention is the ultrafiltration technology in order to provide a kind of MRI or CT radiography parenteral solution, wherein, ultrafiltration adopts polyether sulfone 10kD milipore filter bag, and it is 1 ~ 2m that monolith film envelope amasss
2; This ultrafiltration technology, employ two milipore filter bags to connect, be respectively milipore filter bag 1 and milipore filter bag 2, between two milipore filter bags, sample point is set, to after the filtrate of milipore filter bag 1 is detected, if the bacterial endotoxin level of filtrate is not less than 0.2EU/ml, then filter through milipore filter bag 2, just final filtrate.
Preferably, this ultrafiltration technology comprises the following steps:
(1) backflow end is rinsed: the pure water adding 40 ~ 50 DEG C in purge tank, the water yield is 10L ~ 20L/m
2, flow velocity 10 ~ 201pm/m
2, guarantee in flushing process, do not have liquid to flow back in purge tank;
(2) rinse through end: use 20L ~ 30L/m
2pure water, flow velocity 10 ~ 201pm/m
2, regulate return valve setting pressure 0.5 ~ 2.0bar;
(3) integrity of filtration membranes is tested:
A through filtration and the source of the gas of pressure adjustable joint receives import or the refluxing opening of milipore filter bag;
B slowly be pressurized to the air pressure of specifying, allow residual water discharge;
C measures and records air pressure, temperature and from through mouth gas flow out;
(4) ultrafiltration dialysis: at temperature conditions is 40 ~ 45 DEG C, permeate volume is 500 ~ 1000L;
A makes permeate through milipore filter bag 1, and setting feed rate is 2.5 ~ 4.0L/min/m
2, membrane flux is 300 ~ 500L/h, and the process time is 1.5 ~ 3h, obtains filtrate 1;
B detects the bacterial endotoxin level of filtrate 1, if bacterial endotoxin level is not less than 0.2EU/ml, then make filtrate 1 filter through milipore filter bag 2, setting feed rate is 2.5 ~ 4.0L/min/m
2, membrane flux is 500 ~ 600L/h, and the process time is 1.0 ~ 2.5h, obtains filtrate 2;
The rate of recovery that C detects main ingredient is more than 95%;
(5) rinse filter membrane: first use the phosphate buffer of pH6.8 ~ 8.0 to rinse used milipore filter bag 1 ~ 2 time, then use pure water rinsing 2 ~ 4 times;
(6) ultrafiltration system is cleaned:
A cleaning backflow end: first use 10L ~ 20L/m
2the H of 0.1N
3pO
4solution, then uses 10L ~ 20L/m
20.5N NaOH solution rinse backflow end, flow velocity is 10 ~ 201pm/m
2;
B rinses through end: first use 20L ~ 30L/m
2the H of 0.1N
3pO
4solution, then uses 20L ~ 30L/m
20.5N NaOH solution rinse through end, flow velocity is 10 ~ 201pm/m
2, regulate return valve pressure to be 0.1 ~ 1bar;
(7) preservation of milipore filter bag: the NaOH solution using 0.1N, preserves milipore filter bag at 4 DEG C.
Preferably, polyether sulfone 10kD milipore filter bag is Pellicon2Biomax10kD-A milipore filter bag.Use the milipore filter bag of specific standard can increase the success rate of a ultrafiltration (being used alone milipore filter bag 1), reduce the ratio of two times of ultrafiltration.
Preferably, pure water is deionized water, water for injection or the reverse osmosis water through filtering.
Preferably, described in step (4), the inlet hydraulic of permeate and/or described filtrate 1 is 30 ~ 150psi, and return pressure is 10 ~ 140psi, and the pressure differential of inlet hydraulic and return pressure is 10 ~ 40psi.
Preferably, MRI or CT radiography parenteral solution is selected from: one or more in iohexol inj, iopamidol inj, Iopromide parenteral solution, Iodixanol parenteral solution, ioversol injection, iodinate oil injection, iobitridol parenteral solution, Magnevist Solution parenteral solution, Gadobenate Dimeglumine parenteral solution, Gadobutrol parenteral solution, Gadoxetic acid disodium parenteral solution, gadoterlc acid meglumine saltlniection parenteral solution, gadolinium phosphorus dimension plug three sodium injection, gadodiamide injection, Gadoteric Acid parenteral solution, Gadoversetamide parenteral solution.
Detailed description of the invention
In order to illustrate the present invention further, provide a series of embodiment below.It is pointed out that these embodiments are illustrative completely.The object providing these embodiments is to fully express meaning of the present invention and content, but does not therefore limit the present invention among described scope of embodiments.
Embodiment 1: the ultrafiltration technology of iohexol inj
Use two Pellicon2Biomax10kD-A milipore filter bags to connect as iohexol inj (specification: 350mgI/ml) removes bacterial endotoxin, monolith film envelope amasss as 1m
2, between two milipore filter bags, sample point is set.
(1) backflow end is rinsed: the water for injection adding 40 DEG C in purge tank, the water yield is 10L/m
2, flow velocity 101pm/m
2, guarantee in flushing process, do not have liquid to flow back in purge tank;
(2) rinse through end: use 20L/m
2water for injection, flow velocity 101pm/m
2, regulate return valve setting pressure 0.5bar;
(3) integrity of filtration membranes is tested:
A through filtration and the source of the gas of pressure adjustable joint receives import or the refluxing opening of milipore filter bag, that mouth that best chosen position is higher, close not connecing the import of source of the gas or refluxing opening valve or additive method, permeate mouth is open;
B slowly be pressurized to the air pressure of specifying, then stablize and within five minutes, allow residual water discharge;
C measures and records air pressure, temperature and from through mouth gas flow out, thus determines the integrality of filter membrane.
(4) ultrafiltration dialysis: at temperature conditions is 40 DEG C, permeate volume is 500L;
A makes described permeate through described milipore filter bag 1, and setting feed rate is 2.5L/min/m
2, membrane flux is 300L/h, and inlet hydraulic is 60psi, and return pressure is 50psi, and the pressure differential of inlet hydraulic and return pressure is 10psi, and the process time is 1.5h, obtains filtrate 1;
B detects the bacterial endotoxin level of filtrate 1, and bacterial endotoxin level is less than 0.2EU/ml, and filtrate is no longer by milipore filter bag 2;
The rate of recovery that C detects main ingredient is 99.2%;
(5) rinse filter membrane: first use the phosphate buffer of pH6.8 ~ 8.0 to rinse used milipore filter bag (milipore filter bag 1) 1 time, then use water for injection to rinse 2 times;
(6) ultrafiltration system is cleaned:
A cleaning backflow end: first use 10L/m
2the H of 0.1N
3pO
4solution, then uses 10L/m
20.5N NaOH solution rinse backflow end, flow velocity is 201pm/m
2;
B rinses through end: first use 20L/m
2the H of 0.1N
3pO
4solution, then uses 20L/m
20.5N NaOH solution rinse through end, flow velocity is 201pm/m
2, regulate return valve pressure to be 0.1bar;
(7) preservation of milipore filter bag: the NaOH solution using 0.1N, preserves milipore filter bag at 4 DEG C.
Embodiment 2: the ultrafiltration technology of Gadobenate Dimeglumine parenteral solution
Use two PES polyether sulfone 10kD-A milipore filter bags to connect as Gadobenate Dimeglumine parenteral solution (specification: 529mg/ml) removes bacterial endotoxin, monolith film envelope amasss as 2m
2, between two milipore filter bags, sample point is set.
(1) backflow end is rinsed: in purge tank, add 50.Filtered deionized water, the water yield is 20L/m
2, flow velocity 201pm/m
2, guarantee in flushing process, do not have liquid to flow back in purge tank;
(2) rinse through end: use 30L/m
2filtered deionized water, flow velocity 201pm/m
2, regulate return valve setting pressure 2.0bar;
(3) integrity of filtration membranes is tested:
A through filtration and the source of the gas of pressure adjustable joint receives import or the refluxing opening of milipore filter bag, that mouth that best chosen position is higher, close not connecing the import of source of the gas or refluxing opening valve or additive method, permeate mouth is open;
B slowly be pressurized to the air pressure of specifying, then stablize and within five minutes, allow residual water discharge;
C measures and records air pressure, temperature and from through mouth gas flow out, thus determines the integrality of filter membrane.
(4) ultrafiltration dialysis: at temperature conditions is 45 DEG C, permeate volume is 1000L;
A makes permeate through milipore filter bag 1, and setting feed rate is 3.2L/min/m
2, membrane flux is 450L/h, and inlet hydraulic is 80psi, and return pressure is 60psi, and the pressure differential of inlet hydraulic and return pressure is 20psi, and the process time is 3h, obtains filtrate 1;
B detects the bacterial endotoxin level of filtrate 1, and result bacterial endotoxin level is not less than 0.2EU/ml, then make filtrate 1 filter through milipore filter bag 2, and setting feed rate is 4.0L/min/m
2, membrane flux is 600L/h, and inlet hydraulic is 150psi, and return pressure is 110psi, and the pressure differential of inlet hydraulic and return pressure is 40psi, and the process time is 2.5h, obtains filtrate 2;
The rate of recovery that C detects main ingredient is 96.3%;
(5) filter membrane is rinsed: first use the phosphate buffer of pH6.8 ~ 8.0 to rinse used milipore filter bag (milipore filter bag 1 and milipore filter bag 2) each 2 times, then use filtered deionized water respectively to rinse 4 times;
(6) ultrafiltration system is cleaned:
A cleaning backflow end: first use 20L/m
2the H of 0.1N
3pO
4solution, then uses 20L/m
20.5N NaOH solution rinse backflow end, flow velocity is 101pm/m
2;
B rinses through end: first use 30L/m
2the H of 0.1N
3pO
4solution, then uses 30L/m
20.5N NaOH solution rinse through end, flow velocity is 101pm/m
2, regulate return valve pressure to be 1bar
(7) preservation of milipore filter bag: the NaOH solution using 0.1N, preserves milipore filter bag at 4 DEG C.
Embodiment 3: the ultrafiltration technology of Magnevist Solution parenteral solution
Use two PES polyether sulfone 10kD-A milipore filter bags to connect as Magnevist Solution parenteral solution (specification: 469mg/ml) removes bacterial endotoxin, monolith film envelope amasss as 1.5m
2, between two milipore filter bags, sample point is set.
(1) backflow end is rinsed: the reverse osmosis water adding 45 DEG C in purge tank, the water yield is 15L/m
2, flow velocity 151pm/m
2, guarantee in flushing process, do not have liquid to flow back in purge tank;
(2) rinse through end: use 25L/m
2reverse osmosis water, flow velocity 151pm/m
2, regulate return valve setting pressure 1.0bar;
(3) integrity of filtration membranes is tested:
A through filtration and the source of the gas of pressure adjustable joint receives import or the refluxing opening of milipore filter bag, that mouth that best chosen position is higher, close not connecing the import of source of the gas or refluxing opening valve or additive method, permeate mouth is open;
B slowly be pressurized to the air pressure of specifying, then stablize and within five minutes, allow residual water discharge;
C measures and records air pressure, temperature and from through mouth gas flow out, thus determines the integrality of filter membrane.
(4) ultrafiltration dialysis: at temperature conditions is 42 DEG C, permeate volume is 900L;
A makes permeate through milipore filter bag 1, and setting feed rate is 3.0L/min/m
2, membrane flux is 400L/h, and inlet hydraulic is 70psi, and return pressure is 55psi, and the pressure differential of inlet hydraulic and return pressure is 15psi, and the process time is 2.6h, obtains filtrate 1;
B detects the bacterial endotoxin level of filtrate 1, and bacterial endotoxin level is not less than 0.2EU/ml, and filtrate 1 is filtered through milipore filter bag 2, and setting feed rate is 3.5L/min/m
2, membrane flux is 550L/h, and inlet hydraulic is 120psi, and return pressure is 95psi, and the pressure differential of inlet hydraulic and return pressure is 25psi, and the process time is 2.0h, obtains filtrate 2;
The rate of recovery that C detects main ingredient is 95.8%;
(5) rinse filter membrane: first use the phosphate buffer of pH6.8 ~ 8.0 to rinse used milipore filter bag (milipore filter bag 1 and milipore filter bag 2) each 2 times, then use reverse osmosis water respectively to rinse 3 times;
(6) ultrafiltration system is cleaned:
A cleaning backflow end: first use 15L/m
2the H of 0.1N
3pO
4solution, then uses 15L/m
20.5N NaOH solution rinse backflow end, flow velocity is 151pm/m
2;
B rinses through end: first use 25L/m
2the H of 0.1N
3pO
4solution, then uses 25L/m
20.5N NaOH solution rinse through end, flow velocity is 151pm/m
2, regulate return valve pressure to be 0.5bar;
(7) preservation of milipore filter bag: the NaOH solution using 0.1N, preserves milipore filter bag at 4 DEG C.
The ultrafiltration technology of embodiment 4 Iodixanol parenteral solution
Inventor employs the ultrafiltration that the method for embodiment 1 and parameter achieve Iodixanol parenteral solution (specification: 320mgI/ml).
The ultrafiltration technology of embodiment 5 iopamidol inj
Inventor employs the ultrafiltration that the method for embodiment 1 and parameter achieve iopamidol inj (specification: 370mgI/ml) equally.
Very large due to drug content for MRI or CT radiography parenteral solution, cause product viscosity very large, common ultrafiltration technology is difficult to realize the industrial applications in this field.
Inventor is by improving the ultrafiltration technology of MRI or CT radiography parenteral solution, the creationary series connection that have employed two specific milipore filter bags, best technological parameter and milipore filter bag category are groped, thus achieve the industrial applications of ultrafiltration technology, not only avoid the pH using active carbon removal bacterial endotoxin to bring to decline, and make technique more succinct, ensure the low bacterial endotoxin level in product, reduce further production cost.
It should be noted that, foregoing invention content and detailed description of the invention are intended to the practical application proving technical scheme provided by the present invention, should not be construed as limiting the scope of the present invention.Those skilled in the art in spirit of the present invention and principle, when doing various amendment, equivalent replace or improve.Protection scope of the present invention is as the criterion with appended claims.
Claims (6)
1. a ultrafiltration technology for MRI or CT radiography parenteral solution, is characterized in that, (1) described ultrafiltration adopts polyether sulfone 10kD milipore filter bag, and it is 1 ~ 2m that monolith film envelope amasss
2; (2) described ultrafiltration technology, employ two described milipore filter bags to connect, be respectively milipore filter bag 1 and milipore filter bag 2, between two described milipore filter bags, sample point is set, to after the filtrate of described milipore filter bag 1 is detected, if the bacterial endotoxin level of filtrate is not less than 0.2EU/ml, then filter through described milipore filter bag 2, just final filtrate.
2. the ultrafiltration technology of MRI or CT radiography parenteral solution according to claim 1, it is characterized in that, described ultrafiltration technology comprises the following steps:
(1) backflow end is rinsed: the pure water adding 40 ~ 50 DEG C in purge tank, the water yield is 10L ~ 20L/m
2, flow velocity 10 ~ 201pm/m
2, guarantee in flushing process, do not have liquid to flow back in purge tank;
(2) rinse through end: use 20L ~ 30L/m
2pure water, flow velocity 10 ~ 201pm/m
2, regulate return valve setting pressure 0.5 ~ 2.0bar;
(3) integrity of filtration membranes is tested:
A through filtration and the source of the gas of pressure adjustable joint receives import or the refluxing opening of milipore filter bag;
B slowly be pressurized to the air pressure of specifying, allow residual water discharge;
C measures and records air pressure, temperature and from through mouth gas flow out;
(4) ultrafiltration dialysis: at temperature conditions is 40 ~ 45 DEG C, permeate volume is 500 ~ 1000L;
A makes described permeate through described milipore filter bag 1, and setting feed rate is 2.5 ~ 4.0L/min/m
2, membrane flux is 300 ~ 500L/h, and the process time is 1.5 ~ 3h, obtains filtrate 1;
B detects the bacterial endotoxin level of filtrate 1, if bacterial endotoxin level is not less than 0.2EU/ml, then make filtrate 1 filter through described milipore filter bag 2, setting feed rate is 2.5 ~ 4.0L/min/m
2, membrane flux is 500 ~ 600L/h, and the process time is 1.0 ~ 2.5h, obtains filtrate 2;
The rate of recovery that C detects main ingredient is more than 95%;
(5) rinse filter membrane: first use the phosphate buffer of pH6.8 ~ 8.0 to rinse used milipore filter bag 1 ~ 2 time, then use pure water rinsing 2 ~ 4 times;
(6) ultrafiltration system is cleaned:
A cleaning backflow end: first use 10L ~ 20L/m
2the H of 0.1N
3pO
4solution, then uses 10L ~ 20L/m
20.5N NaOH solution rinse backflow end, flow velocity is 10 ~ 201pm/m
2;
B rinses through end: first use 20L ~ 30L/m
2the H of 0.1N
3pO
4solution, then uses 20L ~ 30L/m
20.5N NaOH solution rinse through end, flow velocity is 10 ~ 201prn/m
2, regulate return valve pressure to be 0.1 ~ 1bar;
(7) preservation of milipore filter bag: the NaOH solution using 0.1N, preserves milipore filter bag at 4 DEG C.
3. the ultrafiltration technology of MRI or CT radiography parenteral solution according to claim 1, is characterized in that, described polyether sulfone 10kD milipore filter bag is Pellicon2Biomax10kD-A milipore filter bag.
4. the ultrafiltration technology of MRI or CT radiography parenteral solution according to claim 2, is characterized in that, described pure water is deionized water, water for injection or reverse osmosis water through filtering.
5. the ultrafiltration technology of MRI or CT radiography parenteral solution according to claim 2, it is characterized in that, described in described step (4), the inlet hydraulic of permeate and/or described filtrate 1 is 30 ~ 150psi, return pressure is 10 ~ 140psi, and the pressure differential of inlet hydraulic and return pressure is 10 ~ 40psi.
6. the ultrafiltration technology of MRI or the CT radiography parenteral solution according to any one of Claims 1 to 5, it is characterized in that, described MRI or CT radiography parenteral solution is selected from: iohexol inj, iopamidol inj, Iopromide parenteral solution, Iodixanol parenteral solution, ioversol injection, iodinate oil injection, iobitridol parenteral solution, Magnevist Solution parenteral solution, Gadobenate Dimeglumine parenteral solution, Gadobutrol parenteral solution, Gadoxetic acid disodium parenteral solution, gadoterlc acid meglumine saltlniection parenteral solution, gadolinium phosphorus dimension plug three sodium injection, gadodiamide injection, Gadoteric Acid parenteral solution, one or more in Gadoversetamide parenteral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410260510.2A CN105268320B (en) | 2014-06-13 | 2014-06-13 | A kind of ultrafiltration technology of MRI or CT radiographies parenteral solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410260510.2A CN105268320B (en) | 2014-06-13 | 2014-06-13 | A kind of ultrafiltration technology of MRI or CT radiographies parenteral solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105268320A true CN105268320A (en) | 2016-01-27 |
| CN105268320B CN105268320B (en) | 2018-03-16 |
Family
ID=55138680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410260510.2A Active CN105268320B (en) | 2014-06-13 | 2014-06-13 | A kind of ultrafiltration technology of MRI or CT radiographies parenteral solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105268320B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113694795A (en) * | 2021-09-27 | 2021-11-26 | 成都倍特药业股份有限公司 | Liquid preparation system and preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5779905A (en) * | 1995-05-16 | 1998-07-14 | Dibra S.P.A. | Process for the depyrogenation of injectable pharmaceutical solutions |
| CN101683318A (en) * | 2008-09-28 | 2010-03-31 | 南京中医药大学 | Method for removing pyrogen from injections |
| CN101961498A (en) * | 2009-07-21 | 2011-02-02 | 通用电气医疗集团股份有限公司 | Endotoxic removal in the contrast agent |
| CN102086234A (en) * | 2009-12-07 | 2011-06-08 | 重庆大新药业股份有限公司 | Preparation method for improving quality of medium molecular weight hydroxyethyl starch |
-
2014
- 2014-06-13 CN CN201410260510.2A patent/CN105268320B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5779905A (en) * | 1995-05-16 | 1998-07-14 | Dibra S.P.A. | Process for the depyrogenation of injectable pharmaceutical solutions |
| CN101683318A (en) * | 2008-09-28 | 2010-03-31 | 南京中医药大学 | Method for removing pyrogen from injections |
| CN101961498A (en) * | 2009-07-21 | 2011-02-02 | 通用电气医疗集团股份有限公司 | Endotoxic removal in the contrast agent |
| CN102086234A (en) * | 2009-12-07 | 2011-06-08 | 重庆大新药业股份有限公司 | Preparation method for improving quality of medium molecular weight hydroxyethyl starch |
Non-Patent Citations (1)
| Title |
|---|
| 刘冬: "《生物分离技术》", 31 December 2007 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113694795A (en) * | 2021-09-27 | 2021-11-26 | 成都倍特药业股份有限公司 | Liquid preparation system and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105268320B (en) | 2018-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016257253B2 (en) | Modular system and method for continuously producing and/or preparing a product in a disinfected manner | |
| JP5778389B2 (en) | Protein purification method | |
| JP2009533092A5 (en) | ||
| JP7218357B2 (en) | Method for treating protein-containing suspension or protein-containing solution | |
| JPH01194991A (en) | Pyrogen removal method | |
| CN105668896A (en) | Purified water preparation system | |
| CN105540966A (en) | Purified water preparation system | |
| CN110582308B (en) | System and method for producing microbial controlled fluids | |
| CN105268320B (en) | A kind of ultrafiltration technology of MRI or CT radiographies parenteral solution | |
| US5779905A (en) | Process for the depyrogenation of injectable pharmaceutical solutions | |
| CN204529543U (en) | Ultrapure water production system | |
| CN103449652A (en) | Preparation method of sterile water for injection | |
| CN211255379U (en) | Double-box inverted electrodialysis water purification system and table top type water purifier thereof | |
| CN102897941A (en) | Medical reverse-osmosis water purification system | |
| CN214654222U (en) | Purified water preparation machine | |
| CN204508987U (en) | Two matter water purifier | |
| CN113694795A (en) | Liquid preparation system and preparation method | |
| CN208279391U (en) | Nanofiltration water system | |
| CN207347312U (en) | Water purifier composite filter element | |
| JP2017104787A (en) | Method of using concentrated water as circulating cooling water | |
| CN205710234U (en) | A kind of Medicine water purification system | |
| JP2005281238A (en) | Medical electrolyte liquid utilizing sea water and method for producing the same | |
| JPH0566821B2 (en) | ||
| CN207845382U (en) | A kind of medicine purified water treatment device | |
| WO2013106657A1 (en) | A water filtration device for the production of medical grade water for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zong Li Inventor after: Hong Chengjie Inventor before: Zong Li |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 101500 No. 3 Shuiyuan West Road, Miyun District, Beijing Patentee after: Beijing BeiLu Pharmaceutical Co., Ltd. Address before: 100082 Maple Blue International Block A 705, 32 Xizhimen North Street, Haidian District, Beijing Patentee before: Beijing BeiLu Pharmaceutical Co., Ltd. |